Skip to content

Investors

Investors

2014 Press Releases

2014 | 2013 | 2012 | Archive
Keyword Search
 
DateTitle 
07/15/14ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
SAN DIEGO--(BUSINESS WIRE)--Jul. 15, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective today. Mr. Davis will report to Uli Hack... 
Printer Friendly Version
06/17/14ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
SAN DIEGO--(BUSINESS WIRE)--Jun. 17, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014, at 1:30 p.m. Eastern Time in New York City. ... 
Printer Friendly Version
05/27/14ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
SAN DIEGO--(BUSINESS WIRE)--May 27, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 10:00 a.m. Eastern Time in New York City. A ... 
Printer Friendly Version
05/06/14ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 6, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2014. ACADIA reported a net loss of $17.8 million, or $0.19 per common share, ... 
Printer Friendly Version
05/01/14ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 1, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, ... 
Printer Friendly Version
04/29/14ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
ACADIA to Host Conference Call and Webcast on Tuesday, May 6, 2014, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 29, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial r... 
Printer Friendly Version
04/01/14ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
SAN DIEGO--(BUSINESS WIRE)--Apr. 1, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m. Eastern Time in New York City. A l... 
Printer Friendly Version
03/05/14ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Cowen and Company 34th Annual Health Care Conference on Wednesday, M... 
Printer Friendly Version
03/04/14ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted... 
Printer Friendly Version
03/03/14ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Mar. 3, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and J.P. Morgan Securities LLC are acting as the j... 
Printer Friendly Version
02/27/14ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013. ACADIA reported a net loss of $12.0 million, or $0.13 per common share,... 
Printer Friendly Version
02/20/14ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
ACADIA to Host Conference Call and Webcast on Thursday, February 27, 2014, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 20, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial resu... 
Printer Friendly Version
back to top